Flexion Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.3M
Doctors Paid
10,183
Transactions
37,550
2020 Total
$2.1M
Payment Breakdown by Category
Research$6.6M (58.2%)
Consulting$1.8M (15.8%)
Food & Beverage$867,939 (7.7%)
Travel$349,908 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 183 | 58.2% |
| Consulting Fee | $1.8M | 502 | 15.8% |
| Honoraria | $1.5M | 613 | 13.5% |
| Food and Beverage | $867,939 | 34,655 | 7.7% |
| Travel and Lodging | $349,908 | 976 | 3.1% |
| Grant | $100,000 | 2 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $91,271 | 29 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,942 | 246 | 0.1% |
| Education | $4,294 | 344 | 0.0% |
Payments by Type
Research
$6.6M
183 transactions
General
$4.7M
37,367 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee | $2.6M | 0 | 22 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | $1.1M | 0 | 58 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis | $661,744 | 0 | 36 |
| A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients with Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip | $386,201 | 0 | 7 |
| An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients with Osteoarthritis of the Knee | $379,060 | 0 | 19 |
| Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee | $322,211 | 0 | 3 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury SLAM | $194,996 | 1 | 1 |
| Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip | $184,942 | 0 | 11 |
| Benefits of IA Injections | $116,025 | 0 | 2 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers A Pilot Feasibility Study | $109,806 | 1 | 1 |
| Zilretta vs. TAcs | $101,600 | 0 | 1 |
| Rotator Cuff | $82,453 | 0 | 1 |
| Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance | $74,012 | 0 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder | $57,625 | 0 | 10 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury (SLAM) | $48,749 | 0 | 1 |
| An open-label pilot study of the effect of intra-articular bilateral knee injections of Zilretta (FX006) on OARSI recommended physical performance measures in adults with knee osteoarthritis. | $45,156 | 0 | 1 |
| Patient- and Physician-Perceived Barriers to and Benefits of Intraarticular Injections for Osteoarthritis: A Qualitative Study | $29,006 | 0 | 1 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers (A Pilot / Feasibility Study) | $27,452 | 0 | 1 |
| A Stratified Investigation of a Single Injection of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for Symptomatic Relief in Patients with Idiopathic Adhesive Capsulitis of the Shoulder. | $24,529 | 0 | 1 |
| A Randomized, Open-label, Parallel Group Study in Patients with Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration into Both Knees of either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) | $20,687 | 0 | 3 |
| Zilretta for Shoulder IAC | $20,441 | 0 | 1 |
| Study to assess the safety and efficacy of FX006 administered to patients with greater trochanteric bursitis | $15,439 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Daniel Rosenthal, Md, MD | Diagnostic Radiology | Boston, MA | $3,125 | $0 |
| Robert Agee, Md, MD | Family Medicine | Birmingham, AL | $3,095 | $0 |
| Dr. Stanley Cohen, M.d, M.D | Rheumatology | Dallas, TX | $3,076 | $0 |
| Dr. David Kaufman, M.d, M.D | Orthopaedic Surgery | Lake Forest, IL | $3,074 | $0 |
| Dr. Brian Busconi, M.d, M.D | Orthopaedic Surgery | Worcester, MA | $3,054 | $0 |
| Jason Koh, Md, MD | Sports Medicine | Skokie, IL | $3,010 | $0 |
| Dr. Michael Redler, M.d, M.D | Sports Medicine | Trumbull, CT | $2,977 | $0 |
| Dr. Charles Hummer, Md, MD | Orthopaedic Surgery | Media, PA | $2,975 | $0 |
| Dr. Matthew Provencher, Md, MD | Sports Medicine | Vail, CO | $2,898 | $0 |
| Dr. Tuhina Neogi, Md, MD | Internal Medicine | Boston, MA | $2,850 | $0 |
| Dr. Kevin Farmer, Md, MD | Sports Medicine | Gainesville, FL | $2,696 | $0 |
| Paul Demarco, Md, MD | Rheumatology | Wheaton, MD | $2,669 | $0 |
| Gregory Soghikian, Md, MD | Sports Medicine | Manchester, NH | $2,650 | $0 |
| Kenneth Kalunian, Md, MD | Rheumatology | San Diego, CA | $2,550 | $0 |
| Amanda Nelson, M.d, M.D | Rheumatology | Chapel Hill, NC | $2,550 | $0 |
| Dr. Ronald Delanois, M.d, M.D | Orthopaedic Surgery | Baltimore, MD | $2,550 | $0 |
| Neil Segal, Md, MD | Dermatology | Iowa City, IA | $2,533 | $0 |
| Howard Blumstein, M.d, M.D | Rheumatology | Smithtown, NY | $2,523 | $0 |
| Matlock Jeffries, Md, MD | Internal Medicine | Oklahoma City, OK | $2,520 | $0 |
| Dr. Khalid Yousuf, M.d, M.D | Orthopaedic Surgery | Plano, TX | $2,514 | $0 |
| Dr. Natasha Desai, M.d, M.D | Sports Medicine | New York, NY | $2,500 | $0 |
| Mark Wichman, M.d, M.D | Orthopaedic Surgery | Wauwatosa, WI | $2,500 | $0 |
| Dr. Svetlana Krasnokutsky, M.d, M.D | Rheumatology | Purchase, NY | $2,500 | $0 |
| David Fisher, Md, MD | Orthopaedic Surgery | Indianapolis, IN | $2,500 | $0 |
| Dr. Marc Hochberg, M.d, M.D | Rheumatology | Baltimore, MD | $2,500 | $0 |
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. has made $11.3M in payments to 10,183 healthcare providers, recorded across 37,550 transactions in the CMS Open Payments database. In 2020, the company paid $2.1M. The top product by payment volume is Zilretta ($10.0M).
Payments were distributed across 117 medical specialties. The top specialty by payment amount is Orthopaedic Surgery ($2.3M to 3,632 doctors).
Payment categories include: Food & Beverage ($867,939), Consulting ($1.8M), Research ($6.6M), Travel & Lodging ($349,908).
Flexion Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.